CRON
Cronos Group Inc
NASDAQ · Pharmaceuticals
$2.64
+0.08 (+3.13%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 155.32M | 133.35M | 685.76M | 608.59M | 622.30M |
| Net Income | 54.22M | 41.89M | 79.65M | 77.66M | 87.35M |
| EPS | — | — | — | — | — |
| Profit Margin | 34.9% | 33.2% | 11.6% | 12.8% | 14.0% |
| Rev Growth | +16.5% | +16.5% | -5.4% | +15.9% | -6.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 460.98M | 544.31M | 499.08M |
| Total Equity | — | — | 649.41M | 682.78M | 653.80M |
| D/E Ratio | — | — | 0.71 | 0.80 | 0.76 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -129,712,059 | -105,801,026 | 131.89M | 120.12M | 125.66M |
| Free Cash Flow | — | — | 54.82M | 67.66M | 69.93M |